Quarterly report pursuant to Section 13 or 15(d)

NET (LOSS) INCOME PER COMMON SHARE (Tables)

NET (LOSS) INCOME PER COMMON SHARE (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

For the three months ended March 31, 2022 and 2021, the average market prices for the periods ended are less than the exercise price of all the outstanding stock options, therefore, the inclusion of the stock options would be anti-dilutive. In addition, for the three months ended March 31, 2022, since the Company has a net loss, the effect of common stock equivalents is anti-dilutive, and, as such, common stock equivalents have been excluded from the calculation. For the three months ended March 31, 2021 since the convertible promissory notes had been converted into common stock, they have been excluded in the Company’s computation of net (loss) income per common share.

	Three Months Ended			Three Months Ended
	March 31, 2022			March 31, 2021
Basic net (loss) income per share computation:
Net (loss) income	$	(40,656	)	$	354,679
Weighted-average common shares outstanding		5,136,177			4,765,292
Basic net (loss) income per share	$	(0.01	)	$	0.07
Diluted net (loss) income per share computation:
Net (loss) income per above	$	(40,656	)	$	354,679
Weighted-average common shares outstanding		5,136,177			4,765,292
Incremental shares attributable to assumed conversion of stock options and warrants		-			1,410
Total adjusted weighted-average shares		5,136,177			4,766,702
Diluted net (loss) income per share	$	(0.01	)	$	0.07

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following table summarizes securities that, if exercised, would have an anti-dilutive effect on (loss) income per share.

Three Months

March 31, 2022

Three Months

March 31, 2021

Stock options

165,620

99,990

Total potential dilutive securities not included in (loss) income per share

165,620

99,990